Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Simeprevir - Medivir/Janssen R&D Ireland

Drug Profile

Simeprevir - Medivir/Janssen R&D Ireland

Alternative Names: Galexos; JNJ-38733214-AAA; Olysio; R-494617; SMV; Sovriad; TMC-435; TMC-435350

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medivir AB
  • Developer Alios BioPharma; Janssen Pharmaceutical KK; Janssen R&D Ireland; Medivir AB
  • Class 3-ring heterocyclic compounds; Antivirals; Cyclopropanes; Quinolines; Small molecules; Sulfonamides; Thiazoles
  • Mechanism of Action Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 19 Feb 2021 No development reported - Phase-II for Hepatitis C (Combination therapy) in Mauritius and Moldova (PO)
  • 11 May 2018 Alios Biopharma completes a phase II trial in Hepatitis C in New Zealand, Moldova, Mauritius, United Kingdom (NCT02569710)
  • 07 May 2018 Janssen completes a phase II trial in Hepatitis C (Combination therapy) in Japan (PO) (NCT02993250)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top